Creative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MORE HighlightsWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORE HighlightsThe advent of Chimeric Antigen Receptor T-cell (CAR-T) therapies has revolutionized the field of oncology, providing new avenues for treating various forms of cancer. Our 20 years of experience in the biotechnology sector have equipped us with the expertise and technological capabilities to support the entire lifecycle of CAR-T products, from early development to commercialization.
EXPLORE MORETo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MORE HighlightsUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
EXPLORE MORE HighlightsGet a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MORE
With first-class skills and rich experience, Creative Biolabs offers services for generation and validation of chimeric T cell receptor (chTCR), which is an attractive strategy to genetically modify and redirect the specificity of T cells in adoptive immunotherapy.
Genetically-modified T lymphocytes expressing T cell receptors (chTCR) specific for tumor cells have been widely investigated for cancer therapy. chTCR is an approach that uses the gene encoding modified TCR or monoclonal antibody chains to endow the TCR with high affinity to tumor associated antigens (TAAs). Typically, chTCR consists of three functional regions: extracellular domains, transmembrane domains and intracellular signaling domains. The extracellular fragments made from TCR or tumor-specific antibody are designed to recognize and bind target cells such as cancer cells. As shown in the figure A, the TCR can be conventional or a single chain and the specific antibody can be Fab or single-chain variable fragment (scFv). ScFv is used more frequently than Fab in recent researches. Transmembrane domain is important to overcome the mispairing of chTCR with endogenous TCR chains. To proliferate and respond on an antigen, T cells relies on the co-stimulatory signals. Accordingly, the transmembrane and intracellular signaling domains may be derived from primary activation molecules, co-stimulatory molecules and intracellular protein kinases, such as CD3ζ or FcεRI. A hinge is constructed for linking the extracellular fragments and signaling domains. Additionally, the modification of primary human T cells from healthy donors could be used to generate humanized chTCR (hchTCR) specific for adoptive T cell immunotherapy for cancers. As the chTCR is not restricted by MHC molecules which natural TCR depends on the generated supernatural T cells can be an ideal tool in cancer therapy.
Creative Biolabs have professional experts from different disciplines to ensure the construction of robust and reliable chimeric receptors targeting your concerned antigens.
To discuss your demands or to request a proposal, please contact us by .
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION
